History

2023
Jun.	Commenced sales of Comlex, an antibacterial otic solution Changed company name to NANO MRNA Co., Ltd.
Mar.	COMLEX (development code: ENT103), an antibacterial otic solution received manufacturing and marketing approval.
Jan.	Converted to a business model specializing in mRNA drug discovery.

2022
Dec.	Shiro Akinaga becomes President & CEO
Apl.	Shifted market listing from the “Mothers” section of the Tokyo Stock Exchange to the “Growth” section. Co-developer Ceolia Pharma Co., Ltd. filed an application for manufacturing and marketing approval of ENT103 for the treatment of otitis media and otitis externa.

2021
Sep.	Accomplishment of Primary Endpoint in Phase III Clinical Study of ENT103（otitis media）
Jun.	Fast Track designationof NC-6300 (Epirubicin Micelle) by the U.S. FDA Started Clinical trial of VB-111 in Japan as part of a joint, global phase III trial involving platinum-resistant ovarian cancer patients (OVAL study) Moved head office in Chuo-ku, Tokyo Moved Lab in kawasaki, Kanagawa VB-111 Phase III clinical trial for platinum-resistant ovarian cancer started in Japan
Apl.	Established AXCELEAD Inc. and PrimRNA Inc.

2020
Sep.	Merged with AccuRna, Inc.

2019
Nov.	Mr.Tetsuhito Matsuyama was inaugurated as President and CEO
Jul.	Started Phase II Clinical Study in Combination with Keytruda® for Squamous Cell Carcinoma of Head and Neck
May	Joint research agreement with iCONM on therapeutic effect in combination with immune checkpoint inhibitor Started Phase III Clinical Study on ENT103 for Patients with Otitis media in Japan with Ceolia Pharma Co., Ltd.
Apl.	Concluded a specified sales agency agreement on Aeon Acti-PRP in Japan with Aeon International Inc.

2018
Oct.	Commercial launch of renewal cosmetic essence “eclafutur d” (Collaboration with ALBION Co., Ltd.)
Jul.	License and Collaborative Agreement with Orient Europharma for Global Study on new approach of using NC-6004 to treat Head and Neck Cancer
Jun.	Joint Development Agreement with Ceolia Pharma Co., Ltd.
Apl.	Capital and Business Alliance between NANO MRNA Co., Ltd., Noritsu Koki Co., Ltd. and Gene Techno Science Co., Ltd.

2017
Nov.	EXCLUSIVE AGREEMENT FOR VB-111 IN JAPAN with VBL THERAPEUTICS
Oct.	JCR Conclude Collaborative Research Agreement for Drug Delivery to the Brain for Nucleic Acid Medicines
Sep.	Depth Brand Started handling at Isetan Shinjuku Release of scalp total care product “Depth For Share” for unisex
Aug	Establishment of US Subsidiary of NANO MRNA Depth brand “Styling series” released
Jul.	Orphan Drug Designationof NC-6300 (Epirubicin Micelle) by the U.S. FDA Orphan Drug Designationof NC-6004 (biliary tract cancer) by the U.S. FDA
Jun.	Started Phase I/II Clinical Study on NC-6300 for Patients with Rare Cancers in the U.S.

2016
Jun.	Started Clinical Study in the EU in Relation to the Expansion of the Area for the Development of NC-6004
May	Licensing Agreement with AccuRna Inc. and Investment in AccuRna Inc.
Apl.	Launch Albion “EXCIA AL IMMACULATE IDD” jointly developed product
Mar.	Launch scalp total care product “Depth” for men

2015
Dec.	Started phase II clinical trial of NC-6004 (basket trial) in USA.
Nov.	Started phaseI clinical study (Head & Neck cancer)of NC-6004 in Japan.
Sep.	NC-6004 to Participate in the Multinational Phase III Clinical Trial in Asia for Indication of Pancreatic Cancer
Jul.	Established iCONM Labo. in kawasaki, Kanagawa.
Mar.	Established Tokyo office in Chuo-ku, Tokyo.
Feb.	Collaborative research agreement for siRNA Drug with Chugai pahrmaceutical Co., Ltd.

2014
Jun.	In-licensed new drug compound “E7974” from Eisai Co., Ltd Moved head office,lab and Tokyo office to new facility near “Kashiwanoha Campus” station in Kashiwa, Chiba.
May	Started phase Ib/II clinical trial of NC-6004 (non small cell lung cancer) in USA.
Feb.	Orient Europharma started Phase III clinical study (pancreatic cancer) of NC-6004 in Asia

2013
Dec.	Started phase I clinical trial of NC-4016 in USA.
Oct.	Commercial launch of new cosmetic essence “eclafutur”(Collaboration with ALBION Co., Ltd.)
Sep.	KOWA company Ltd. started Phase I clinical study of NC-6300 (K-912) in Japan
Jun.	Collaborative research agreement for polymer with Shin-Etsu Chemical Co., Ltd. Orient Europharma submitted IND　for Phase III clinical study (pancreatic　cancer) of Nanoplatin® (NC-6004) in Asia IND submission for Phase Ib/IIclinical study (non small cell lungcancer) of Nanoplatin®, (NC-6004) in USA
May	IND submission for Phase I clinical　study of DACH-platinum micelle(NC-4016) in USA Kowa submitted IND for Phase I　clinical study of NC-6300 (K-912) in Japan

2012
Nov.	NC-6004 New Licensing Agreement Between NANO MRNA and Orient Europharma.
Oct.	Started phase Ｉ clinical trial of Nanoplatin (NC-6004) in Japan. Equity investment by Shin-Etsu Chemical Co., Ltd. into NANO MRNA by private placement.
Jul.	Collaboration Agreement On Development of New Cosmetic Compounds with ALBION Co., Ltd. Nippon Kayaku Co., Ltd. started phase III clinical trail(Breast Cancer) of Paclitaxel Micelle (NK105).
Mar.	Collaborative research agreement with Eisai Co., Ltd.

2011
Sep.	Worldwide license and co-development Agreement of Epirubicin Micelle (NC-6300) with KOWA company Ltd.
Jul.	Started phase Ⅱ clinical trial of Nanoplatin (NC-6004) in Taiwan&Singapore.

2010
Dec.	Collaborative research agreement with National Cancer Center to initiate a preclinical study of Epirubicin Micelle(NC-6300).
Oct.	Option agreement of protein micelle for rhFVIIa with LFB Biotechnologies.
Aug.	Nippon Kayaku Co., Ltd. started phase I clinical trail(Breast Cancer) of Paclitaxel Micelle (NK105).

2009
May	In-licensed “Cationic Polyamino Acids” from the University of Tokyo and TOUDAI TLO, Ltd.
Mar.	Started phase I clinical trial of DACH-platin Micelle (NC-4016) in EU.

2008
Dec.	IND Application of Nanoplatin® for Phase I/II study was approved in Taiwan
Sep.	License and co-development Agreement of Nanoplatin (NC-6004) with Orient Europharma Co., Ltd.
Apr.	Exclusive License Agreement signed with Toudai TLO, Ltd. on Incorporated Nucleic Acids into Micelles
Mar.	NANO MRNA got listed on the Tokyo Stock Exchanges Mothers

2007
Nov.	Nippon Kayaku Co., Ltd. started phase II clinical trail(gastric cancer) of Paclitaxel Micelle (NK105).
Feb.	In-licensed “A new block copolymer for preparation of pH-sensitive polymeric micelle and a production process thereof” from the University of Tokyo and TOUDAI TLO, Ltd.

2006
Aug.	In-licensed “Physical trapping type polymeric micelle drug preparation”, for the research and development of paclitaxel micelle (NK105) with Japan Science and Technology Agency.
Jul.	Obtained exclusive license of “Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon” from TOUDAI TLO, Ltd.
May	Started phase I clinical trial of Nanoplatin® (NC-6004) in U.K.

2005
Jul.	Formed partnership with TOUDAI TLO, Ltd for “discovery and development of drugs with high usability for treatment of solid cancers”.
Mar.	Formed partnership with Debiopharm S.A. for DACH-Platin micelle (NC-4016).

2004
Aug.	Moved head office and lab to Tohdai Kashiwa Venture Plaza in Kashiwa, Chiba.
May	Nippon Kayaku Co., Ltd., a licensed company in Japan, started phase I clinical trial of Paclitaxel Micelle (NK105). In-licensed “Coordinate complex of diaminocyclohexaneplatinum (II) with block copolymer containing poly (carboxylic acid) segment and antitumor agent comprising the same” from the University of Tokyo and TOUDAI TLO, Ltd.

2003
Jul.	Established Tokyo office in Chuo, Tokyo.

2002
Jun.	Out-licensed Paclitaxel Micelle to Nippon Kayaku Co., Ltd.

2001
Jan.	In-licensed “Polymeric micelle containing cisplatin enclosed therein and use thereof” from the Center for Advanced Science and Technology Incubation Ltd. (now TOUDAI TLO, Ltd.).

1999
Oct.	Moved head office to Tokatsu Techno Plaza in Kashiwa, Chiba, and established the lab.

1997
Aug.	Formed partnership with Nippon Oil & Fats Co., Ltd. (now NOF Corporation) on joint development and supply of a new block copolymer (after then, entered into a supply agreement on exclusive manufacture and supply of polymer on December 2003).

1996
Jun.	Founded in Setagaya, Tokyo, with the purpose of applying new block copolymers to develop pharmaceuticals and put them into practice.